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Abstract: 
The reaction of hydrogen peroxide and certain aromatic aldehydes with cytochrome P450BM3-F87G results in 
the covalent modification of the heme cofactor of this monooxygenase. Analysis of the resulting heme by 
electronic absorption spectrophotometry indicates that the reaction in the BM3 isoform is analogous to that in 
P4502B4, which apparently occurs via a peroxyhemiacetal intermediate [Kuo et al., Biochemistry, 38 (1999) 
10511]. It was observed that replacement of the Phe-87 in the P450BM3 by the smaller glycyl residue was 
essential for the modification to proceed, as the wild-type enzyme showed no spectral changes under identical 
conditions. The kinetics of this reaction were examined by stopped-flow spectrophotometry with 3-
phenylpropionaldehyde and 3-phenylbutyraldehyde as reactants. In each case, the process of heme modification 
was biphasic, with initial bleaching of the Soret absorbance, followed by an increase in absorbance centered at 
430 nm, consistent with meso-heme adduct formation. The intermediate formed during phase I also showed an 
increased absorbance between 700 and 900 nm, relative to the native heme and the final product. Phase I 
showed a linear dependence on peroxide concentration, whereas saturation kinetics were observed for phase II. 
All of these observations are consistent with a mechanism involving radical attack at the γ-meso position of the 
heme cofactor, resulting in the intermediate formation of an isoporphyrin, the deprotonation of which produces 
the γ-meso-alkyl heme derivative. 
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1. INTRODUCTION 
 
The proposed catalytic cycle of cytochrome P450 consists of multiple reactive oxygen species, each capable, in 
theory, of initiating substrate oxidation. The oxenoid iron (Fe
V
=O) intermediate has gained widespread 
acceptance as an oxygenating agent. This intermediate, proposed over 25 years ago, is central to the oxygen-
rebound mechanism, which accounts for the many stereochemical and regiochemical results observed in 
cytochrome P450-catalyzed hydroxylation reactions [1–3]. Further studies of alcohol [4] and aldehyde [5] 
oxidation and N-oxygenation [6] reactions also point to an analogous cytochrome P450 intermediate during 
catalysis. In fact, it is widely assumed that the majority of oxidative chemical transformations effected by 
cytochrome P450 enzymes occur via the obligatory formation of the oxenoid iron intermediate. This 
intermediate, referred to as compound I, has been well characterized in the peroxidases [7], a related class of 
enzymes that, like P450, contain a heme prosthetic group. Direct observation of the ‘compound I-like’ 
intermediate in the P450CAM reaction cycle was first accomplished through the use of stopped-flow experiments 
in which m-chloroperoxybenzoic acid was used as an oxygen surrogate, by-passing the electron transfer and 
oxygen binding steps in the cycle [8]. More recently, an X-ray crystal structure of an apparent oxo-ferryl 
intermediate of P450CAM, the decomposition of which results in hydroxylated camphor, has appeared in the 
literature [9], leaving little doubt that oxenoid iron plays a critical role in catalysis. 
 
In 1982, Akhtar et al. [10] proposed that a ferric-peroxo intermediate formed prior to the oxenoid iron was 
directly responsible for the terminal step in the demethylation of androgens to estrogens by the enzyme P450-
aromatase. Using model substrates intended to mimic the structure of the physiological androgens, Roberts et al. 
[11] and Vaz et al. [12] showed that purified liver microsomal enzymes were able to catalyze the analogous 
deformylation of xenobiotic aldehydes. Subsequent studies involving the use of site-directed mutagenesis 
showed that aldehyde deformylation and substrate hydroxylations by P4502B4 utilize different activated oxygen 
intermediates in catalysis, with deformylation occurring, most likely, via a nucleophilic attack of a ferric peroxo 
species at the electropositive carbonyl carbon to form a transient peroxohemiacetal [13] (Scheme I). 
 
Studies by Raner et al. [5] involving aromatic aldehydes showed that for a single substrate, both oxenoid-iron 
and peroxo-iron metabolic routes are available. With certain aldehydes, heme modification was observed, and 
subsequent studies by Kuo et al. [14] indicated that the modification results from addition of a deformylated 
reaction product to the γ-meso position of the heme cofactor in P4502B4. 
 
Although indirect chemical evidence for the occurrence of the peroxy-hemiacetal intermediate in aldehyde de-
formylation is compelling, no direct evidence for its existence has been offered. In this study we have used 
stopped-flow spectrophotometry in an attempt to directly observe intermediates in the peroxide-dependent 
alkylation of the heme cofactor in cytochrome P450 by the aromatic aldehydes 3-phenylpropionaldehyde (3-PP) 
and 3- phenylbutyraldehyde (3-PB). We have chosen to work with the bacterial enzyme P450BM3 because it 
offers several advantages over the liver microsomal counterparts; in particular, the enzyme is cytosolic and can 
be easily purified from the recombinant strain of E. coli in which it is produced. The X-ray crystal structure of 
P450BM3 has been solved, providing detailed structural information regarding substrate access and potential 
steric interactions within the active site [15]. Of the five bacterial P450s for which X-ray structural data are 
available, the BM3 isoform is the best model for the microsomal enzymes on the basis of its utilization of an 
analogous cytochrome P450 reductase redox partner. None of the other bacterial enzymes accept electrons from 
this type of flavoprotein. Finally, the BM3 enzyme is a functional fusion protein combining the P450 oxygenase 
enzyme and reductase in a single poly- peptide, which eliminates the necessity for dual purification procedures 
and subsequent reconstitution. 
 
 
 
Although advantageous in many ways, the use of BM3 in this study presented several obstacles. The native 
BM3 is a fatty acid hydroxylase with a correspondingly selective active site structure. The crystallographic 
data indicate that a phenylalanine residue at position 87 controls substrate entry into the active site cavity, 
which could preclude the use of the bulky aromatic aldehydes chosen for this study. Graham-Lorence et al. 
[16] first reported on a mutant form of BM3 in which the Phe87 residue was replaced by site-directed 
mutagenesis with a Val. This mutation altered the regiospecificity of the enzyme, presumably by allowing 
deeper penetration of the fatty acid substrate into the heme pocket. In addition, Schwaneberg et al. [17] 
reported higher rates of hydroxylation of p-nitrophenoxydodecanoic acid using the F87A mutant of BM3 
relative to the wild- type form. We have therefore chosen to work with an analogous mutant form, F87G, in 
which Gly was the replacement for Phe. The complete removal of the aromatic side chain was expected to 
facilitate binding of bulkier substrates. An additional concern was the finding of Davis et al. [18] that fatty 
aldehyde substrates were oxidized to the corresponding diacids by P450BM3 with no observed deformylation 
products in reactions that utilized NADPH and molecular oxygen in catalysis. The study did not, however, 
examine the use of hydrogen peroxide as an oxygen donor. Previous studies using the liver enzymes suggest 
that the use of peroxide can enhance the rate of deformylation relative to other oxidative pathways [5]. To test 
whether P450BM3 can catalyze deformylation reactions using hydrogen peroxide as an oxygen source was one 
of the objectives of the current study. 
 
2. EXPERIMENTAL SECTION 
 
2.1. Chemicals 
The compounds 3-phenylpropionaldehyde and 3- phenylbutyraldehyde were purchased from Sigma (St. Louis, 
MO). All reagents used in the growth and induction of E. coli were from Fisher. Q-Sepharose and 2',5'-ADP 
agarose used for enzyme purification were from Pharmacia (Piscataway, NJ). 
 
2.2. Enzyme preparations 
Cytochrome P450BM3-F87G was expressed in E. coli using a clone generously provided by Dr. David Mullin, 
Tulane University. Cells were grown in TB media at room temperature to an optical density of nearly 3.0, with 
shaking at 120 rev./min. Induction was accomplished by addition of 0.15 g/l IPTG, and the cells were incubated 
an additional 6–24 h at room temperature with reduced shaking (70 rev./min). Following enzymatic lysis, and 
sonication in 50 mM phosphate buffer (pH 7.4), 0.1 mM EDTA, containing 20% glycerol, the cytosolic material 
was separated from the cell debris by centrifugation (2.5 h at 54,000Xg). Purification of the wild-type and F87G 
mutant were carried out as described previously [19]. Approximately 50 to 100 mg of highly purified enzyme 
were produced per l bacterial culture. Enzyme concentrations were determined as described by Omura and Sato 
[20] using e450=96 mM
-1
. 
 
2.3. Stopped-flow experiments 
Experiments were carried out at 22°C using a Hi-Tech Model SF-61 stopped-flow spectrophotometer equipped 
with an MG6000 diode array. The integration time for each spectrum was 10 ms, with the time interval between 
scans determined by the duration of the individual experiment. Data were collected using Hi-Tech software and 
hardware installed on a DX2 Gateway 2000 66 MHz computer. From the diode array data, single wavelength 
traces at 418, 427, and 434 nm were extracted and analyzed by a two- sequential exponential fitting routine 
contained in the Hi-Tech software. 
 
Reactions were initiated by the rapid mixing of a solution containing 6.0 µM cytochrome P450BM3-F87G, 2.5 
mM aldehyde, and 100 mM phosphate buffer (pH 7.4) with an equal volume of a solution containing 100 mM 
phosphate buffer (pH 7.4) and various concentrations of hydrogen peroxide. Two different aldehydes were 
examined in this study, 3-PP and 3-PB, with a range of hydrogen peroxide concentrations from 100 µM to 600 
µM. 
 
2.4. Purification and analysis of the modified hemes 
P450BM3-F87G (20 µM) was incubated with 100 µM H2O2 in the presence of 2.5 mM 3PB at 12°C for 15 min in 
25 ml of 100 mM phosphate buffer (pH 7.4). Reactions were monitored spectrally at 434 nm to ensure complete 
conversion of wild-type heme to the corresponding modified derivative. The sample was bound to a Q-
Sepharose (Pharmacia) anion exchange column equilibrated in 100 mM phosphate (pH 7.4) to remove excess 
aldehyde and unreacted H2O2. After the column had been washed with five volumes of 50 mM phosphate 
buffer, pH 7.4, the modified enzyme was eluted using 400 mM phosphate buffer, pH 7.4. The enzyme was 
precipitated by acidification to pH 3.0 using TFA, and the solid was collected by centrifugation. Under these 
conditions, the heme remained attached to the protein, while the flavins were released into the supernatant 
solution. Treatment of the pellets with 100% acetonitrile, containing 0.1% TFA, resulted in nearly complete 
extraction of the heme. Acetonitrile was evaporated and the resulting pellet was dissolved in 5.0 ml 50:50 
acetonitrile:H2O containing 0.1% TFA. The sample was injected onto a Higgins HAIsil C18 HPLC column 
(250X 4.6 mm), using a Rheodyne 7012 injector valve with 5.0 ml injection loop, at a flow rate of 1.0 ml/min. 
The HPLC system consisted of an LC-10AT dual pumping unit, an SCL-10A controlling unit, an FCV-10AL 
quaternary mixing chamber, a DGU-14A in-line degassing unit, an SPD-M10A diode array detector, and an 
SIL-10A autosampler, all interfaced to an Ast Bravo LC 5166M computer operating with a CLASS -VP 
automated software system. The mobile phase for this sample was 50:50 acetonitrile:H2O, containing 0.1% 
TFA. Under these conditions, the retention time of the modified heme was 18.6 min, whereas that of the native 
cofactor was 10.1 min. The sample was recovered and the 50% acetonitrile solution was diluted 1:3 with H2O 
and passed through a C18 reversed phase solid phase extraction device. The heme was bound tightly to this 
column under these conditions. The column was washed with 50 volumes of 40:60 and 50:50 acetonitrile:H2O 
mixtures (both containing 0.1% TFA), the heme was eluted in 100% methanol with 0.1% TFA. Heme purified 
by this procedure did not appear to be altered during the extraction procedure. To confirm this, we injected a 
50-µl sample of the enzyme, modified by H2O2 and 3PB treatment, directly onto the HPLC column under the 
conditions described above. We then injected a 50-µl sample of the modified heme we obtained by the 
purification method described. The HPLC retention times and absorption spectra of the alkylated hemes were 
the same. 
 
The effect of aldehyde structure on retention time was examined using the aldehydes phenylacetaldehyde (PA), 
3PP, and 4-phenylbutyraldehyde (4PB). The reaction of BM3-F87G with each aldehyde was carried out as 
described for 3PB above, and the resulting modified enzymes were injected directly onto a C18 HPLC column 
with a mobile phase of 60:40 acetonitrile:H2O containing 0.1% TFA at a flow rate of 1.0 ml/min. 
 
For the determination of the extinction coefficient of the modified heme, samples were taken directly from an 
analytical HPLC preparation in the mobile phase described previously, and examined by atomic absorption 
spectroscopy (Perkin Elmer 272 Atomic Absorption Spectrometer). The ε408 was determined using the 
combined atomic and electronic absorption data. 
 
Electronic absorption spectra for the wild-type, and modified hemes, along with their respective holo-enzymes 
were recorded on a HP8453 diode array spectrophotometer. All spectrophotometric, kinetic, and 
chromatographic data were then imported into Slidewrite (Advanced Graphics Software Inc.). 
 
3. RESULTS 
 
3.1. Characterization of the modified hemes 
Addition of 100 µM hydrogen peroxide to cytochrome P450BM3-F87G in the presence of saturating levels of the 
aromatic aldehydes 3-PP and 3-PB resulted in the formation of an enzyme species with its Soret peak shifted 
from 418 nm to 430 nm (Fig. 1). Wild-type P450BM3 did not undergo the same spectral changes under these 
conditions, but exhibited only a rather slow loss of heme absorbance (data not shown). The shift in the Soret 
peak of the F87G mutant enzyme results from the chemical modification of the heme group and corresponding 
spectral changes for the free heme (Fig. 2). The λmax for wild-type heme is 398 nm, whereas the heme 
derivatives generated in this study show λmax values of 408 nm. HPLC analysis of the free modified and native 
hemes indicated a relationship between the size of the aldehyde used in the experiment and the retention time of 
the product heme. For example, we chose a series of unbranched aromatic aldehydes that differed only in the 
number of methylene carbons in the chain. Retention times of 6.4, 8.0, 10.9, and 12.3 min were observed for the 
native, PA, 3PP, and 4PB modified hemes, respectively. This is consistent with previous studies involving the 
rabbit liver microsomal enzyme P4502B4, in which a series of aldehydes with different molecular weights were 
examined [5]. The heme produced in the reaction with 3-PB was analyzed by atomic absorption spectroscopy to 
determine the molar extinction coefficient. A sample with an A408=0.805 was shown to have an iron content of 
7.7 µM, giving an ε408 of 104,000 M
-1
 cm
-1
. 
 
 
3.2. Stopped-flow experiments 
The reaction of P450BM3-F87G with 3-PB proceeded in at least two phases as indicated by the kinetic trace 
shown in Fig. 3, illustrating the change in absorbance at 426 nm within the first 90 s after mixing (426 nm was 
chosen because it best illustrated the biphasic nature of the reaction). Phase I was characterized by a decrease in 
absorbance over nearly the entire wavelength range. An increase in absorbance was observed in the 700–900 
nm range during this first phase of the reaction (Fig. 4). Phase II consisted of an increase in absorbance centered 
at 430 nm, with a loss of the absorbance near 850 nm that originated in phase I. The spectral changes between 
320 and 700 nm for each phase, as a function of time, are shown in Fig. 5. The temperature at which the 
experiments were carried out significantly effected the rates of both 
 
 
 
 
phases, as well as the amount of heme adducts formed. For example, higher reaction temperatures appeared to 
result in greater amounts of heme degradation (not shown). Experi- 
 
 
ments were therefore carried out at 22°C. The effects of light on the reaction were also examined; by reducing 
the light intensity using a stainless wire mesh as a filter, and increasing the integration time from 1.25 to 10 ms, 
we were able to reduce the amount of spectral bleaching without loss of sensitivity. With 3PP, the observed rate 
constants, k1 and k2, associated with phases I and II, respectively, were sensitive to hydrogen peroxide 
concentration. As the concentration of 3PP was varied from 100 to 600 µM, k1 increased from 0.037 to 0.124s
-1
, 
and k2 increased from 0.012 to 0.044 s
-1
 as determined at 427, 418 and 434 nm. Although k1 displayed a linear 
dependence on H2O2 concentration, k2 showed saturation behavior. Qualitatively, our results with 3-PP were 
identical to those obtained with the branched aldehyde; however, with 3PB, the k2 values were somewhat 
smaller (0.017 s
-1
 at 600 µM H2O2), which had the effect of increasing the half-life of the spectral intermediate. 
Plots of observed k1 values vs. H2O2 concentration for 3PP and 3PB are shown in Fig. 6a. Fig. 6b shows double 
reciprocal plots of the data for k2, from which we can extrapolate values for k2 at infinite H2O2 concentration, or 
theoretical maximum values for k2. For 3PP, this value was approximately sixfold higher than for 3PB. 
 
4. DISCUSSION 
 
Heme adduct formation in cytochrome P450, as a consequence of exposure to aldehydes and hydrogen 
peroxide, has been examined previously with the microsomal isoform 2B4 [5,14]. In these studies it was shown 
that the aldehyde undergoes loss of the carbonyl carbon and the resulting radical species attacks the heme 
prosthetic group at the γ-meso position. In the current study, we have examined the analogous heme 
modification process in the bacterial isoform P450BM3 (F87G mutant) using stopped-flow spectrophotometry in 
an attempt to characterize reaction intermediates. That P450BM3-F87G is capable of this type of transformation 
was evident from the spectral changes accompanying treatment with H2O2 and 3PP. We have confirmed that 
Phe-87 prevents binding of aromatic substrates by our observation that analogous spectral changes do not occur 
in the wild-type enzyme under identical reaction conditions. 
 
Modification of the heme by an aldehyde-derived species was verified using several different structurally 
related aldehydes including PA, 3PP, and 4PB. Although each of the aldehydes produced a heme adduct in the 
presence of H2O2 and P450BM3-F87G, and each heme adduct had a λmax of 408 nm, the retention times of the 
adducts by HPLC correlated strongly with the size of the parent aldehyde, with larger more hydrophobic 
compounds producing heme adducts with longer retention times. 
 
Spectral analysis of the modified heme cofactor generated in P450BM3-F87G strongly suggests a mechanism 
 
 
involving peroxo-iron. For example, Kuo et al. [14] showed that with P4502B4, aldehydes can be activated by 
either the peroxo-pathway or the oxenoid iron pathway to form heme adducts. The two products are distinct, 
however, in their electronic absorption properties, with the peroxo-derived adduct possessing a maximum 
absorbance at 408 nm, vs. 402 nm for the oxenoid-iron-derived species. The adducts described in the current 
paper all have a λmax of 408 nm. The most likely position of attack, on the basis of the known crystal structure 
of the BM3 enzyme, is the γ-meso carbon, just as in P4502B4. For example, Fig. 7 shows the active site structure 
of P450BM3 based on the crystal studies of Li and Poulos [15] (PDB file 2BMH). In the F87G mutant, removal 
of the bulky aromatic ring of Phe leaves a void in the active site. Aromatic substrates such as 3PP or 3PB might 
be expected to effectively fill this void in the enzyme. Distances between the phenyl ring carbons on Phe 87 in 
the wild-type enzyme and the heme γ-meso position range from 
 
 
3.86 A, for the Phe-ε-carbon facing the heme, to 6.28 Å, for the Phe-δ-carbon facing away from the heme. None 
of the other heme meso carbon atoms lie within 5.9 Å of any of the phenyl ring positions, and most are more 
than 7 Å away. Therefore, based on proximity, the most likely site for attachment of the phenylethyl radical, 
generated in the deformylation of 3PP, would be the γ-meso position of the heme. 
 
We used stopped-flow spectrophotometry to examine the physical properties of intermediates in the reaction of 
aldehydes and H2O2 with P450BM3-F87G. Two aldehydes were chosen for the study, as each could be used to 
generate a heme adduct in high yield (>80%), and heme degradation in these samples was minimal. The 
reaction with both aldehydes was biphasic, with the first phase consisting of a general bleaching of the spectrum 
in the visible region. The bleached spectrum is consistent with a heme that has lost some of its aromaticity, 
similar to compound I, in which a π-electron has been removed from the porphyrin macrocycle. Unlike 
compound I, however, this intermediate displays a maximum absorbance at 426 nm rather than 367, as reported 
by Egawa et al. [11]. Furthermore, absorbance increases in the 700–900 nm region, as observed in this 
experiment, have been associated with isoporphyrin spectra [21], but not P450 compound I, which has an 
absorption band centered at 694 nm. An isoporphyrin intermediate (Fig. 8) has been proposed in the reaction of 
HRP with cyclopropanone hydrate and with alkyl hydrazines [22,23]. These additions occur at the δ-meso 
position on the heme, while reactions of alkylhydrazines with myoglobin produce γ-meso alkylated hemes [24]. 
In each of these cases, the isoporphyrin is produced as a result of a free radical attack at a meso carbon on the 
porphyrin. A similar mechanism can easily be envisaged in the inactivation of P450BM3-F87G by 
 
aldehydes, as the peroxo-pathway results in alkyl radical formation. Using 3PP, a phenylethyl radical is 
predicted, giving rise to a meso-phenylethyl-isoporphyrin species much like the one generated in studies by 
Ator et al. [21] using phenylethyl hydrazine and HRP. 
 
Kinetic analysis of intermediate formation and decay using both 3PP and 3PB allowed us to assess the relative 
stability of the corresponding isoporphyrin intermediates. The rate of formation in each case was linearly 
dependent on the hydrogen peroxide concentration. The second order rate constants were 1.4X 10
-2
 and 1.02X 
10
-2
 min
-1
 µM
-1
 for 3PB and 3PP, respectively. The data suggest that structural differences in the two aldehydes 
have little effect on the rate of activation, that is, deformylation with radical formation. The two substrates differ 
significantly, however, in the apparent deprotonation rate of their respective isoporphyrin intermediates. Here, 
the deprotonation refers to the loss of a proton from the γ-meso-carbon of the isoporphyrin. As H2O2 
concentration increases, the k2 values for each of the two aldehydes approaches a maximum value, indicative of 
a first order process, dependent only on the steady-state level of isoporphyrin present. Double reciprocal 
analysis of the data give the theoretical maximum values for k2 of 1.07 and 6.0 min
-1
 for 3PB and 3PP, 
respectively. The sixfold lower k2 for the 3PBdependent reaction, relative to that of the 3PP, is intriguing since 
the aldehydes differ by a single methyl group on C-2 of the propionyl chain, and k2 presumably represents acid 
dissociation of the isoporphyrin. In an attempt to understand this difference in deprotonation rate, we examined 
the analogous heme modification in P4502B4 with the intent of determining a value for k2. For this isoform, 
heme adduct formation was observed, as described previously [5]; however, the reaction appeared to be 
monophasic, with no evidence for the formation of an isoporphyrin intermediate. Two factors may contribute to 
this observation; phase I of this reaction was slightly slower than phase I for the BM3 isoform. Secondly, phase 
II, which is suggested to be deprotonation of the isoporphyrin, may be substantially faster in 2B4. The 
combined effect of these would be masking of the isoporphyrin intermediate. 
 
The difference in k2 between P4502B4 and P450BM3- F87G is presumably the result of differences in their active 
site geometries, and the corresponding differences in the interactions between the isoporphyrin intermediate and 
the active site of the enzyme. For example, in BM3-F87G, the enhanced stability of the isoporphyrin may result 
from strong binding interactions between the aldehyde phenyl group and the vacant Phe-87 site within the 
enzyme. This rationalization is illustrated in Scheme II. The phenylethyl radical produced in the deformylation 
of 3PP is ideally positioned for attack on the γ-meso carbon from above the plane of the porphyrin (Fig. 8), with 
the resulting formation of a putative isoporphyrin intermediate (step 1). According to the X-ray crystal 
structure, the formation of this intermediate would not require significant movement of the bound phenyl ring. 
However, for deprotonation to occur, the phenyl ring must move down toward the plane of the porphyrin in 
order to achieve the resulting aromatic heme structure (step 2). This may involve the extraction of the phenyl 
ring from its binding site, posing a kinetic barrier to deprotonation. If movement of the alkyl group toward the 
plane of the porphyrin influences intermediate stability, then it is a logical conclusion that as the steric bulk of 
the side chain increases, as is the case in going 
 
 
 
from 3PP to 3PB, the rate of deprotonation should also decrease. Since the γ-meso carbon is flanked by 
propionate groups, the potential for steric interactions at this position is considerable. This model provides a 
qualitative explanation for the observed kinetics. 
 
In conclusion, we report here the first direct evidence for an isoporphyrin intermediate in the inactivation of a 
cytochrome P450 enzyme. This proposed intermediate is mechanistically consistent with the observed alkylated 
heme product, and the intermediate spectra are very similar to those reported by Ator et al. [23] for isoporphyrin 
intermediates in the modification of horseradish peroxidase. 
 
5. ABBREVIATIONS 
 
2B4  cytochrome P4502B4 
BM3-F87G cytochrome P450BM3 with Phe-87 mutated to Gly 
PA  phenylacetaldehyde 
3PB  3-phenylbutyraldehyde 
4PB  4-phenylbutyraldehyde 
3PP  3-phenylpropionaldehyde 
TFA  trifluoroacetic acid 
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